ACAD — ACADIA PHARMACEUTICALS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1070494 ·
Last close
$25.87
Market Cap
$4.43B
52W High
$27.31
52W Low
$20.30
ADV30
1,735,863
Next earnings
2026-08-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 268,062,000 | 243,271,000 | -4,616,000 | 3,637,000 | 1,605,230,000 | 282,212,000 | 357,164,000 |
| Dec 2025 | 283,989,000 | 257,764,000 | 17,391,000 | 273,568,000 | 1,564,195,000 | 177,695,000 | 336,805,000 |
| Sep 2025 | 278,633,000 | 256,986,000 | 35,756,000 | 71,779,000 | 1,330,771,000 | 257,996,000 | 413,499,000 |
| Jun 2025 | 264,566,000 | 243,832,000 | 32,374,000 | 26,666,000 | 1,225,555,000 | 253,637,000 | 403,173,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$109,836,000
Investing CF
$-302,564,000
Financing CF
$49,883,000
CapEx
$-99,976,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$2.29
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,813,386,000
Inventory
$34,670,000
Receivables
$148,231,000
ST Investments
$641,991,000
EBIT TTM
$104,811,000
Pretax Income TTM
$138,904,000
Interest Exp TTM
—
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,095,250,048
EBITDA
$92,707,000
Free Cash Flow
$154,138,624
Enterprise Value
$3,629,208,064
Total Cash
$851,457,984
Total Debt
$50,794,000
Shares Out
171,235,870
Trailing EPS
$2.21
Book Value
$7.29
ROE
37.3%
ROA
3.7%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,071,505,000 | 104,811,000 | 391,000,000 | 1,564,195,000 | 336,805,000 | — | 109,836,000 |
| Dec 2024 | 957,797,000 | 84,279,000 | 226,451,000 | 1,187,756,000 | 454,963,000 | — | 157,719,000 |
| Dec 2023 | 726,437,000 | -73,379,000 | -61,286,000 | 748,956,000 | 317,201,000 | — | 16,702,000 |
| Dec 2022 | 517,235,000 | -223,596,000 | -215,975,000 | 587,812,000 | 187,399,000 | — | -114,035,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.85
Max Pain — expiry 2026-09-18
max pain strike: $23.00 · spot: $25.87 · call oi: 3,597 · put oi: 1,514
Expected Move to 2026-09-18:
±$5.22
(20.20%) —
implied range
$20.65 –
$31.10
· ATM straddle on $26.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | $4.43B | $27.18 | — |
| MANE | Veradermics, Inc | $4.39B | $105.00 | — |
| GIFLF | Grifols SA | $4.33B | $10.25 | — |
| GIKLY | Grifols SA | $4.31B | $5.10 | — |
| DYN | Dyne Therapeutics, Inc. | $4.70B | $25.18 | — |
News headlines (Yahoo Finance, 1h cache)
Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-07-30 21:57 · Yahoo
HRMY or ACAD: Which Is the Better Value Stock Right Now?
2026-07-30 15:40 · Yahoo
ACADIA Pharmaceuticals (ACAD) Stock Still Looks Below Fair Value Despite Clinical Risk
2026-07-30 12:09 · Yahoo
Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
2026-07-29 14:00 · Yahoo
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
2026-07-28 14:00 · Yahoo
The Zacks Analyst Blog Highlights CVS Health, Cardinal Health, Humana and ACADIA Pharmaceuticals
2026-07-28 09:02 · Yahoo
The Zacks Analyst Blog Highlights Harmony Biosciences, Acadia Pharmaceuticals, Biogen, Insmed and Agios Pharmaceuticals
2026-07-28 08:58 · Yahoo
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
2026-07-27 16:36 · Yahoo
4 Medical Stocks With the Right Setup for Q2 Earnings Beats
2026-07-27 16:03 · Yahoo
Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?
2026-07-27 15:11 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.